U.S. Electronic Equipment and Components Stock News

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...

Mirion Technologies (NYSE:MIR) is facing material trade policy uncertainty after the US administration imposed new 15% global tariffs under the Trade Act of 1974. The tariffs follow a recent Supreme Court ruling and are being implemented abruptly, affecting companies with international supply chains. For Mirion, the policy shift raises questions around cost structure, operational planning, and future financial results. Mirion Technologies, trading at $21.49, now sits at the center of a...

In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure. On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees...

Expro Group Holdings (NYSE:XPRO) has authorized a new $100 million share repurchase program. The company has secured a major multi-year contract in North Africa with an initial four-year term. Recent earnings included higher margins and free cash flow, alongside softer revenue in certain regions. Expro Group, a global energy services provider listed on the NYSE as XPRO, is active across well construction, well flow management, and subsea services. The mix of a sizable buyback authorization...

Corcept Therapeutics FY 2025 earnings snapshot Corcept Therapeutics (CORT) has wrapped up FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.24, alongside net income of US$25.4 million. Over the past six quarters, the company has seen revenue move from US$181.9 million in Q4 2024 to a range between US$157.2 million and US$207.6 million per quarter, while basic EPS has ranged between US$0.19 and US$0.45. With a trailing 12 month net profit margin of 13.1% compared to 20.7% a...

Pebblebrook Hotel Trust (NYSE:PEB) recently completed a $450 million senior unsecured term loan. The company used part of the proceeds to repay certain mortgages and address near term debt maturities. Management also restored full capacity on its revolving credit facility, increasing available liquidity. Pebblebrook Hotel Trust, trading at $12.24, has had mixed share performance, with a 6.0% return year to date and a 4.6% return over the past year, but weaker 3 year and 5 year returns of...

If you are wondering whether Perfect's current share price reflects its true worth, this breakdown will help you connect the recent market action to what the numbers actually say about value. Perfect's share price closed at US$1.38, with returns of a 5.5% decline over 7 days, a 17.4% decline over 30 days, a 20.2% decline year to date, a 27.7% decline over 1 year and 81.9% and 86.1% declines over 3 and 5 years. This performance sits against a backdrop of ongoing market attention on software...

ONEOK (NYSE:OKE) reported double digit net income and adjusted EBITDA growth for 2025. The company exceeded synergy targets from recent acquisitions, including Magellan, and retired a significant amount of long term debt. ONEOK raised its quarterly dividend by 4% and continued integrating acquired assets through 2025. Management outlined plans for 2026 that include expansion into fee based earnings and energy solutions for data centers. ONEOK is a large midstream operator focused on natural...

Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...

Universal Insurance Holdings FY 2025 Earnings Snapshot Universal Insurance Holdings (UVE) has wrapped up FY 2025 with fourth quarter total revenue of US$407.9 million and basic EPS of US$2.40, alongside net income of US$66.6 million as investors weigh these results against a year where net profit margin moved from 3.9% to 11.4% and earnings growth was very large at about 210.5% year over year. Over recent periods the company has seen total revenue shift from US$384.8 million and basic EPS of...

If you are wondering whether Chemours is offering good value at its current price, or if the recent moves are signaling something else about the stock, this article focuses squarely on what the numbers say about value. Chemours' share price closed at US$18.02, with returns of 14.1% over the last 30 days, 47.1% year to date and 16.9% over the past year, while the 7-day return of a 14.8% decline and longer term 3-year and 5-year returns of 42.4% and a 16.4% decline show a mixed picture for...

First Citizens BancShares (FCNCA) has wrapped up FY 2025 with Q4 total revenue of US$2.4b and basic EPS of US$45.78, alongside net income of US$566m that feeds into a trailing 12 month net profit margin of 23.8%, compared with 29.1% a year earlier. Over recent periods, the bank has seen total revenue move between US$2.1b and US$2.4b per quarter and quarterly EPS range from US$34.47 to US$49.18. This gives investors a clear set of numbers to weigh against a five year earnings growth rate of...

Capri Holdings (NYSE:CPRI) has appointed Tyler Reddien as its new Chief Financial Officer and Chief Operating Officer. Reddien steps into the dual role as the company pursues its plans in the global luxury fashion market. Capri Holdings, the owner of luxury brands in the global fashion and accessories space, now has a single executive overseeing both its finance and operations functions. For investors, a combined CFO and COO role can concentrate responsibility for capital allocation, cost...

SPX Technologies (SPXC) has wrapped up FY 2025 with fourth quarter revenue of US$637.3 million and basic EPS of US$1.57, while trailing twelve month revenue came in at about US$2.3 billion alongside EPS of US$5.13. Over the past few quarters the company has seen revenue move from US$533.7 million in Q4 2024 to US$637.3 million in Q4 2025, with basic EPS stepping from US$1.22 to US$1.57 over the same period. Those results sit on top of trailing earnings growth of 21.7% and a net margin of...

Cytokinetics (CYTK) has capped FY 2025 with Q4 revenue of US$17.8 million and a basic EPS loss of US$1.52, anchored by a net loss of US$183.0 million. This sets the tone for how investors are reading the latest update against a year of heavy spending. Over recent periods, the company has seen quarterly revenue range from US$1.6 million to US$66.8 million in FY 2025, while basic EPS losses have moved between US$1.12 and US$2.55. This gives a clear picture of a business that is still investing...

Range Resources (RRC) has wrapped up FY 2025 with fourth quarter revenue of US$913.9 million and basic EPS of US$0.75, alongside net income excluding extra items of US$178.0 million, capping a year where trailing twelve month revenue reached US$3.1 billion and EPS came in at US$2.77. Over the past year the company has seen revenue move from US$2.4 billion to US$3.1 billion on a trailing basis, while net income excluding extra items has gone from US$265.0 million to US$658.0 million and basic...

If you are wondering whether Air Lease is still offering value at its current share price, this article will walk through what the numbers actually say about the stock. With the share price at US$64.85 and returns of 0.1% over 7 days, 0.7% over 30 days, 1.1% year to date, 36.8% over 1 year, 57.7% over 3 years and 50.1% over 5 years, many investors are asking whether expectations and valuation are now in sync. Recent news on Air Lease has focused on its role in supplying aircraft to airlines...

Taboola.com (TBLA) closed out FY 2025 with Q4 revenue of US$522.3 million and basic EPS of US$0.17, alongside Q4 2024 figures of US$491.0 million in revenue and basic EPS of US$0.10. Over the latest reported periods, revenue has moved from US$433.0 million in Q3 2024 to US$496.8 million in Q3 2025, while basic EPS shifted from a loss of US$0.02 to a profit of US$0.02. This highlights a story in which improving profitability and tighter margins are front and center for investors assessing this...

In the past quarter, Gladstone Land Corporation reported fourth-quarter 2025 sales of US$41.45 million and net income of US$4.21 million, alongside full-year 2025 revenue of US$88.34 million and net income of US$13.53 million. The sharp year-over-year improvement in quarterly sales and earnings contrasts with softer full-year sales, highlighting how recent operational performance may be shifting for this farmland-focused REIT. Next, we’ll consider how this strong quarterly earnings growth,...

Keurig Dr Pepper (KDP) has wrapped up FY 2025 with fourth quarter revenue of US$4.5 billion and basic EPS of US$0.26, setting the tone for how investors assess the full year. The company has seen quarterly revenue move from US$4.1 billion in Q4 2024 to US$4.5 billion in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 to EPS of US$0.26 over the same period, against a trailing twelve month EPS of US$1.53. With trailing net margin at 12.5% and earnings growth highlighted over the...

In February 2026, Gentherm reported fourth‑quarter 2025 earnings showing net income falling to US$2.99 million from US$15.32 million a year earlier, while quarterly revenue of about US$382.79 million came in ahead of expectations. Alongside weaker profitability, Gentherm issued product revenue guidance of US$1.5 billion to US$1.6 billion for 2026 and US$1.7 billion for 2027, highlighting its ambition to grow beyond automotive into medical and other precision thermal applications. We’ll now...

Twist Bioscience, NasdaqGS:TWST, has entered a co exclusive licensing agreement with Invenra Inc. for Invenra's B Body bispecific antibody platform. The deal expands Twist's antibody discovery services and includes an equity investment and licensing terms that share economics between the two companies. This move adds bispecific antibody capabilities to Twist's existing biologics discovery tools, broadening the range of programs it can support for biotech and pharma customers. Twist...